AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20881954
Drug: S-warfarin (CYP2C9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-warfarin (CYP2C9 specific) with pazopanib
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 80 mg + Lisinopril 40 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 80 mg + Lisinopril 20 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 80 mg + Lisinopril 10 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 40 mg + Lisinopril 40 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 20 mg + Lisinopril 40 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 20 mg + Lisinopril 20 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 40 mg + Lisinopril 20 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 40 mg + Lisinopril 10 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 20 mg + Lisinopril 10 mg
Trial: 20883929
Drug: High-dose dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dobutamine stress MRI
Trial: 20885982
Drug: OCD-like behaviours
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCD-like behaviours correlated with higher scores of complex tics, neuroleptic and SSRIs treatment frequency, and less successful socio-professional adaptation.
Trial: 20886200
Drug: Long-acting bronchodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting bronchodilator (LABD) monotherapy
Trial: 20888065
Drug: PF-3512676 (0.08,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-3512676 (0.08, 0.16, 0.24, 0.28, 0.32, or 0.36 mg/kg) administered as 24 weekly subcutaneous injections
Trial: 20888102
Drug: Once-daily extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily extended-release niacin
Trial: 20890189
Drug: Daptomycin at
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin at 8 mg/kg intravenously over 30 mins
Trial: 20890189
Drug: Daptomycin at
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin at 8 mg/kg every 48 hrs
Trial: 20919852
Drug: Busulfan AUC
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan AUC of 5800 µmol-min/L
Trial: 20919852
Drug: Busulfan AUC
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan AUC of 6800 µmol-min/L
Trial: 20919852
Drug: Busulfan test
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan test dose
Trial: 20919852
Drug: Busulfan conditioning
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan conditioning dose 1 pharmacokinetics
Trial: 20920156
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (0.5 mg/24 h to 4 mg/24 h, mean daily dose 2.93 ± 1.14 mg/24 h after 2 years)
Trial: 20920370
Drug: IV alpha-1
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV alpha-1 antitrypsin (AAT) augmentation therapy (Alfalastin® or Prolastin®)
Trial: 20920778
Drug: IL-4/IL-13 antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-4/IL-13 antagonist
Trial: 20921437
Drug: Upgrades to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upgrades to or revised cardiac resynchronization therapy device (cohort 2)
Trial: 20921906
Drug: Deferiprone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (50 to 100 mg/kg/d)
Trial: 20922800
Drug: Apricoxib 400
RxNorm normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apricoxib 400 mg/day plus erlotinib 150 mg/day
Trial: 20922800
Drug: Apricoxib 100
RxNorm normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apricoxib 100 mg/day
Trial: 20922800
Drug: Apricoxib 200
RxNorm normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apricoxib 200 mg/day
Trial: 20922800
Drug: Apricoxib 400
RxNorm normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apricoxib 400 mg/day
Trial: 20922800
Drug: Prior EGFR-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior EGFR-directed therapies
Trial: 20923256
Drug: PTH(1-84) 100
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH(1-84) 100 µg once daily for 36 months
Trial: 20923544
Drug: Apatinib (YN968D1)
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (YN968D1) 850 mg once daily
Trial: 20923544
Drug: Apatinib (YN968D1)
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (YN968D1) 750 mg once daily
Trial: 20923561
Drug: CKD patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD patients with e-GFR ≤ 90 ml/min (Group 2)
Trial: 20923561
Drug: CKD patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD patients with 60 ml/min ≤ e-GFR < 90 ml/min (Group 3)
Trial: 20923561
Drug: CKD patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD patients with 15 ml/min ≤ e-GFR < 60 ml/min (Group 4)
Trial: 20923629
Drug: Minocycline augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline augmentation of pharmacotherapy
Trial: 20924570
Drug: Vaginal suppository
RxNorm normalized name: Vaginal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppository containing 1,200 mg miconazole
Trial: 20925950
Drug: Dihydrocapsiate (DCT)
RxNorm normalized name: dihydrocapsaicin
DrugBank: Dihydrocapsiate (DB15398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocapsiate (DCT) 9 mg/day
Trial: 20925950
Drug: Dihydrocapsiate (DCT)
RxNorm normalized name: dihydrocapsaicin
DrugBank: Dihydrocapsiate (DB15398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocapsiate (DCT) 3 mg/day
Trial: 20926537
Drug: Hormonal interventions
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal interventions (specific hormones not detailed)
Trial: 20926818
Drug: Microperimetry treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microperimetry treatment (one eye randomized to treatment)
Trial: 20930086
Drug: Autologous MSC
RxNorm normalized name: AUTOLOGOUS MSC-NTF
DrugBank: Debamestrocel (DB17934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous MSC infusion
Trial: 20930628
Drug: IDO inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDO inhibitors (oral administration)
Trial: 20932222
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg to 120 mg daily
Trial: 20934233
Drug: Irinotecan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (150 mg/m(2))/oxaliplatin (85 mg/m(2)) followed by etoposide (100 mg/m(2)×3)/carboplatin (AUC 6)
Trial: 20935227
Drug: Resveratrol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 0.5 g daily for 29 days
Trial: 20935227
Drug: Resveratrol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 1.0 g daily for 29 days
Trial: 20935227
Drug: Resveratrol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 2.5 g daily for 29 days
Trial: 20935227
Drug: Resveratrol 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 5.0 g daily for 29 days
Trial: 20937945
Drug: Intrathecal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal and intravenous administration of autologous mesenchymal stem cells (MSCs). Mean (SD) of 63.2 × 10(6) (2.5 × 10(6)) MSCs injected. Follow-up ≤25 months.
Trial: 20938098
Drug: 3-month dual
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month dual antiplatelet therapy (aspirin 100-200mg + clopidogrel 75 mg daily)
Trial: 20943702
Drug: Waist circumference,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waist circumference, BMI, blood pressure, plasma glucose, insulin, HOMA-IR
Trial: 20946651
Drug: Personal Concerns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal Concerns Inventory interview plus treatment as usual
Trial: 20947286
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg twice daily with 12 weeks of behavioral counseling
Trial: 20950306
Drug: Bicalutamide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (150 mg) monotherapy
Trial: 20952514
Drug: Bortezomib 1
RxNorm normalized name: bortezomib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1 mg/m2
Trial: 20952517
Drug: Liposomal cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal cytarabine (50 mg) given intrathecally together with systemic or intrathecal dexamethasone once every 2 weeks
Trial: 20952687
Drug: UCB Treg
RxNorm normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB Treg infusion (0.1-30 × 10(5) UCB Treg/kg)
Trial: 20955442
Drug: Adalimumab (160/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (160/80 mg at weeks 0/2 for induction, 40 mg every other week for maintenance)
Trial: 20955619
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli RNA fragments (20, 40, or 60 mg starting dose, escalated to a maximum of 80 mg)
Trial: 20955619
Drug: Yeast RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast RNA fragments (20, 40, or 60 mg starting dose, escalated to a maximum of 80 mg)
Trial: 20955619
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli RNA fragments (60 and 80 mg doses)
Trial: 20956472
Drug: sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib (400 mg orally twice a day)
Trial: 20956472
Drug: non-neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-neoadjuvant treatment
Trial: 20958975
Drug: Benzodiazepines as
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines as adjuvant therapy
Trial: 20961630
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of bone marrow-derived stem cells
Trial: 20961818
Drug: AquADEKs® softgels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AquADEKs® softgels daily for 12 weeks
Trial: 20961907
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment (specifics not provided)
Trial: 20961907
Drug: Antilymphocyte antibody
RxNorm normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilymphocyte antibody administration
Trial: 20962148
Drug: 25 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg/d cholecalciferol supplementation for 4 weeks
Trial: 20962148
Drug: Controlled intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled intake providing 5 μg vitamin D and 1117 mg Ca/d
Trial: 20964499
Drug: Amisulpride (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (400 mg/day)
Trial: 20966039
Drug: Oxygen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen treatment for symptomatic familial pulmonary fibrosis
Trial: 20967484
Drug: UCN-01 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCN-01 at 90 mg/m² over 3 h on cycle 1, reduced to 45 mg/m² over 3 h for subsequent cycles, every 21 days
Trial: 20978276
Drug: Marqibo (vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marqibo (vincristine sulfate liposome injection, VSLI)
Trial: 20979469
Drug: Crizotinib (PF-02341066)
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib (PF-02341066) at a dose of 250 mg twice daily in 28-day cycles
Trial: 20980795
Drug: AS03(A)-adjuvanted H1N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA) after Dose 1
Trial: 20980795
Drug: AS03(A)-adjuvanted H1N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA) after Dose 2
Trial: 20980795
Drug: AS03(A)-adjuvanted H1N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA)
Trial: 20980933
Drug: 10-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-valent pneumococcal conjugate vaccine (PHiD-CV)
Trial: 20980933
Drug: DTPw-HBV/Hib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw-HBV/Hib and poliovirus vaccines
Trial: 20981545
Drug: 3-aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP)
RxNorm normalized name: γ-Aminopyridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP) plus gemcitabine (1,000 mg/m2 on days 1, 8, and 15 every 28 days)
Trial: 21030496
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg every 3 weeks) and fotemustine (100 mg/m² on days 1, 8, and 15, repeated after 4 weeks)
Trial: 21030558
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo anti-CD3/anti-CD28 costimulated autologous T cells + pneumococcal conjugate vaccine + multipeptide tumor antigen vaccine
Trial: 21030558
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccine only
Trial: 21030579
Drug: Upper tertile
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper tertile of GFR (GFR>4.13 ml/min per 1.73 m2)
Trial: 21030579
Drug: Anuric patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anuric patients (urinary output<100 ml/24 h)
Trial: 21737309
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg alteplase
Trial: 21034418
Drug: c-SN6j (chimeric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c-SN6j (chimeric anti-ENG monoclonal antibody)
Trial: 21035624
Drug: Armodafinil 100
RxNorm normalized name: armodafinil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 100 mg PO
Trial: 21035624
Drug: Armodafinil 250
RxNorm normalized name: armodafinil 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 250 mg PO
Trial: 21035955
Drug: Vandetanib 100
RxNorm normalized name: vandetanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 100 mg daily with SRS
Trial: 21041183
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg i.v. every 2 weeks) plus Erlotinib (150 mg/d orally)
Trial: 21041705
Drug: Alemtuzumab 10
RxNorm normalized name: alemtuzumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab 10 mg/d intravenously for 10 days
Trial: 21042071
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin treatment for male pattern baldness
Trial: 21042103
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green 4 mg per injection
Trial: 21042103
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green 6 mg per injection
Trial: 21042103
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green 2 mg per injection
Trial: 21045179
Drug: Gamma imaging
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma imaging (740-mBq technetium 99m sestamibi injection)
Trial: 21047224
Drug: Everolimus (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (3.0 mg/m² orally)
Trial: 21047225
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (SGN-35) at a dose of 0.1 to 3.6 mg per kilogram of body weight every 3 weeks
Trial: 21047927
Drug: High-calorie diet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie diet, relative physical inactivity, and administration of prednisolone (37.5 mg/d) for 12 days
Trial: 21051557
Drug: High-dose lenalidomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lenalidomide (50 mg daily for up to 2 cycles)
Trial: 21051557
Drug: Low-dose lenalidomide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lenalidomide (10 mg daily after HD lenalidomide)
Trial: 21051706
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (0.05 mL) treatment
Trial: 21055747
Drug: Quinagolide (25-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinagolide (25-75 μg/d) administered for 18-20 weeks after L1
Trial: 21055747
Drug: Quinagolide (25-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinagolide (25-75 μg/d)
Trial: 21059672
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg/day s.c.) and MTX
Trial: 21060028
Drug: Cediranib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib at 12 mg/m(2)/d
Trial: 21060028
Drug: Cediranib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib at 8 mg/m(2)/d
Trial: 21060028
Drug: Cediranib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib at 17 mg/m(2)/d
Trial: 21062137
Drug: Aliskiren/valsartan/HCT (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/valsartan/HCT (12.5 or 25 mg)
Trial: 21062428
Drug: Standard photon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard photon treatment
Trial: 21069335
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m(2)) and Docetaxel (75 mg/m(2))
Trial: 21069335
Drug: Pemetrexed and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed and Docetaxel (escalating doses)
Trial: 21070142
Drug: Artesunate 6
RxNorm normalized name: artesunate 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate 6 mg/kg/day for 7 days
Trial: 21070142
Drug: Artesunate 4
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 4 mg/kg/day for 7 days
Trial: 21070142
Drug: Artesunate 2
RxNorm normalized name: Artesunate 25 mg and mefloquine (as mefloquine hydrochloride) 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate 2 mg/kg/day for 7 days
Trial: 21071497
Drug: Deferasirox therapy
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox therapy (mean dose 36.1 ± 7.7 mg/kg/d during the second year)
Trial: 21073392
Drug: Lansoprazole (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (median dose 90 mg/day)
Trial: 21075272
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules (MS-sNT)